aerovatetx.com (JBIO) - Long-Term Debt to Capital Coefficient
Aerovate Therapeutics Inc (JBIO) develops innovative inhaled therapies for pulmonary vascular diseases. Management has revised its development strategy following clinical setbacks, ensuring transparency in capital allocation. This chart on GURU.Markets reflects the value of 0.00, while the business relies on R&D without current sales, leading to a rapid cash burn of investment resources.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvypeoku.ae-7b8ozy8&start=20220704&end=20261101&filename=GURU_Markets_-_JBIO_-_Aerovate-Therapeutics-Inc_-_Long-Term-Debt-to-Capital "JBIO: Aerovate Long-Term Debt to Capital 04/30/2025 - 11/01/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Aerovate Therapeutics, Inc. (JBIO)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Aerovate Therapeutics Inc|JBIO - Long-Term Debt to Capital|Short-Term Debt to Capital Aerovate|JBIO - Company Total Debt|Debt to Net Assets Ratio Aerovate Therapeutics|JBIO - Company Long-Term Debts|Short-Term Debt Volume Aerovate Therapeutics Inc|Quick Liquidity Indicator aerovatetx.com
- net income and valuation ratios data:
General company analysis:aerovatetx.com - JBIO
This ratio determines the degree of the company's dependence on debt financing with a maturity of over one year, comparing long-term liabilities to equity to assess financial stability and interest expense risks. By analyzing the long-term debt-to-equity ratio, an investor can evaluate how aggressively Aerovate Therapeutics Inc (JBIO) finances the development of its innovative inhaled drugs for the therapy of pulmonary hypertension.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|Septerna Corp - Long-Term Debt to Capital|PVLA - Long-Term Debt to Capital|SVRA: Long-Term Debt to Capital|Long-Term Liabilities to Capital rigel.com (RIGL)|Long-Term Debt to Equity AnaptysBio|ATXS: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity enGene Bio (ENGN)|RAPT - Long-Term Liabilities to Capital|Aclaris Therapeutics - Long-Term Debt to Equity Ratio|kyvernatx.com - Long-Term Debt to Equity|Tiziana Life Sciences Ltd - Long-Term Debt to Capital|CABA - Long-Term Debt to Capital|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|THTX: Long-Term Loans to Capital Ratio|AVTX (Avalo Therapeutics, Inc) - Long-Term Debt to Capital|Long-Term Liabilities to Capital eledon.com ELDN|Long-Term Debt to Equity Ratio AGEN (Agenus Inc.)|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Zura Bio Limited - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio ATYR (aTyr Pharmaceuticals)|Adagene Corp - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient IMA (ImageneBio Inc)|STTK: Long-Term Debt to Capital|Long-Term Liabilities to Capital Equillium (EQ)|Long-Term Debt to Equity Connect Biopharma Holdings|IMUX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ATRA|Long-Term Debt to Capital inflarx.de (IFRX)|Long-Term Debt to Equity X4 Pharmaceuticals, Inc. XFOR|ACET (Adicet Bio Inc.) - Long-Term Liabilities to Equity|Celularity Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital INmune Bio Corporation|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Equity Ratio|kezarlifesciences.com (KZR) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio SABS|AKTX (Akari Therapeutics PLC) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital ENLV|Ratio of Long-Term Indebtedness to Capital q32bio.com|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|EDSA - Long-Term Debt to Equity Ratio|IBIO - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Carisma Therapeutics CARM|XTLB (XTL Biopharmaceuticals, Ltd.) - Long-Term Debt to Equity Ratio|Bolt Biotherapeutics, Inc. - Long-Term Debt to Capital Coefficient|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|Aptevo (APVO) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity AIM ImmunoTech (AIM)|aditxt.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GRI (GRI Bio Corp)|XRTX - Long-Term Debt to Equity Ratio|HIND - Long-Term Debt to Equity|revbiosciences.com - Long-Term Loans to Capital Ratio|INDP: Long-Term Debt to Capital|SCNI (Scinai Immunotherapeutics Ltd) - Long-Term Debt to Equity|CALI (CalciMedica Inc) - Long-Term Debt to Capital|Affimed Therapeutics (AFMD) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Allakos Inc. (ALLK)|HOOK - Long-Term Liabilities to Capital|Long-Term Debt to Equity IGM Biosciences IGMS|ITOS (iTeos Therapeutics Inc) - Long-Term Liabilities to Equity|Ocean Bio - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient TCBP (TC BioPharm Ltd)|THRD: Long-Term Debt to Capital